Processa Pharmaceuticals, Inc. PCSA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Processa Pharmaceuticals, Inc. (PCSA) is a healthcare company listed in the US with a market value of about $5M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -248%.
About Processa Pharmaceuticals
Processa Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3962% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | — | — | — | — | $5000 |
| Net income | -$14M | -$12M | -$11M | -$27M | -$11M | -$14M | -$3M | -$4M | -$2M | -$2M |
| Free cash flow | — | -$11M | -$8M | — | — | — | — | — | -$2M | -$2M |
| EPS (diluted) | $-10.36 | $-96.78 | $-211.93 | $-850.96 | $-18.74 | $-63.48 | $-17.49 | $-17.74 | $-10.50 | $-12.25 |
| Net margin | — | — | — | — | — | — | — | — | — | -38341.3% |
| ROIC | -198.1% | -540.0% | -176.1% | -282.4% | -45.4% | -61.0% | -40.5% | -36.8% | -50.5% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Processa Pharmaceuticals pay a dividend?
Not currently.
Is Processa Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Processa Pharmaceuticals scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.